Kim C, Kim JS, Kim H, et al. - Given continuing antiplatelet therapy (APT) has been generally advised during noncardiac surgery, but whether preoperative discontinuation of APT has been avoided or harmful among patients with second‐generation drug‐eluting coronary stents, is still uncertain, and to address this topic, researchers used a multicenter cohort in Korea to evaluate patients undergoing noncardiac surgery following second‐generation drug‐eluting coronary stent implantation. They assessed net adverse clinical events (all‐cause death, major adverse cardiac events, and major bleeding) within 30 days postoperatively. In this patient population, preoperative discontinuation of APT was documented in almost half of patients. Findings revealed that the risk of perioperative adverse events was not significantly influenced by the discontinuation of APT, except that reduced hemorrhagic risk in patients undergoing intra‐abdominal surgery may be achieved by discontinuing APT.